OSE Immunotherapeutics KOL Webinar on Non-Small Cell Lung Cancer by Dr. Stephen Liu and Prof. Benjamin Besse

OSE Immunotherapeutics recently hosted a notable webinar featuring key opinion leaders in the oncology field to discuss advancements and unmet needs in non-small cell lung cancer (NSCLC). The event took place on June 12, 2024, and included prominent figures such as Dr. Stephen Liu, an associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center, and Prof. Benjamin Besse, a medical oncologist and director of clinical research at the Gustave Roussy Institute.

The primary focus of the webinar was to explore the current therapeutic landscape and the development of OSE Immunotherapeutics' innovative cancer vaccine, Tedopi®. This vaccine is designed to activate tumor-specific T-cells and has shown promising results in clinical trials, making it the company's most advanced product in development.

OSE Immunotherapeutics is a biotech firm committed to creating pioneering treatments in the fields of immuno-oncology (IO) and immuno-inflammation (I&I). Their diverse pipeline includes a variety of first-in-class clinical candidates. Tedopi®, for instance, has demonstrated positive outcomes in a Phase 3 trial (Atalante 1) for NSCLC patients who have shown secondary resistance after failing checkpoint inhibitor treatments. Other ongoing Phase 2 trials are exploring Tedopi® in combination therapies for solid tumors.

The company's pipeline also features OSE-279, an anti-PD1 agent, which has shown encouraging results in Phase 1/2 trials for solid tumors. OSE-127, also known as lusvertikimab, is a humanized monoclonal antibody targeting the IL-7 receptor, currently in Phase 2 trials for ulcerative colitis and preclinical research for leukemia.

Another significant candidate is FR-104/VEL-101, an anti-CD28 monoclonal antibody, being developed in collaboration with Veloxis Pharmaceuticals for transplantation purposes. This candidate is undergoing Phase 1/2 trials in renal transplant patients, with a successful Phase 1 trial already completed in the United States.

OSE Immunotherapeutics is also working on an anti-SIRPα monoclonal antibody in partnership with Boehringer Ingelheim for advanced solid tumors and cardiovascular-renal-metabolic (CRM) diseases. This candidate has shown positive Phase 1 results in both monotherapy and combination treatments, with a Phase 2 trial for CRM diseases expected to start by the end of 2024.

Moreover, the company is developing OSE-230, a ChemR23 agonist monoclonal antibody, in collaboration with AbbVie. This candidate is aimed at treating chronic inflammation.

The company leverages three proprietary drug discovery platforms to advance its ambitious goals of delivering next-generation immunotherapies. The Pro-resolutive mAb platform focuses on resolving inflammation by targeting neutrophils and macrophages. OSE-230 is the first candidate from this platform, with other discovery programs underway.

The Myeloid Checkpoint platform aims to enhance the therapeutic potential of myeloid cells in immuno-oncology by targeting immune regulatory receptors on macrophages and dendritic cells. The most advanced candidates from this platform, BI 765063 and BI 770371, are being developed in collaboration with Boehringer Ingelheim, showing positive preclinical results.

Lastly, the BiCKI® Platform is a bifunctional fusion protein platform that combines the anti-PD1 backbone with new immunotherapy targets to improve anti-tumor efficacy.

OSE Immunotherapeutics expects its innovative platforms to generate substantial value, supporting its mission to provide groundbreaking immunotherapies. The company continues to make significant strides in its research and development efforts, with numerous clinical trials and partnerships aimed at addressing some of the most pressing medical needs in oncology and immunology.